False Positive Peripheral Blood Culture in Children With Leukaemia: A Prevalence Study
1 other identifier
observational
100
1 country
1
Brief Summary
Chemotherapy, the main treatment for childhood leukemia, has side effects on healthy cells. One of the most important of these side effects is the risk of infection due to neutropenia. In clinics, blood culture is the gold standard for the detection of possible infection risk (bacteremia, fungemia, etc.). During the diagnosis and treatment process in children with leukemia, a large number of peripheral or catheter blood cultures are performed. When the culture results are positive, it is accepted that the infection has grown. In some cases, a positive peripheral blood culture result may not be clinically significant. An agent belonging to the skin flora of the patient or the healthcare professional taking the field culture may also cause the blood culture result to be positive. This is called contamination or false positive blood culture. Contaminated cultures may cause prolonged hospitalization, additional medical interventions, unnecessary initiation of antibiotic treatment and related antibiotic resistance, toxicity due to additional drugs and an increase in hospital costs. The peripheral blood culture contamination rate, which is accepted as a quality indicator in some countries, should be below 3%. In this context, this study aimed to determine the prevalence of false positive peripheral blood cultures by examining the peripheral blood culture results obtained during routine follow-ups from children hospitalized with leukemia in the pediatric hematology clinic. The data will be collected retrospectively covering three years before March 2024 when the ethics committee approval was obtained. Since the relevant clinic cares for approximately 25 new children diagnosed with leukemia annually, the study sample is planned as 75 cases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 15, 2024
CompletedFirst Submitted
Initial submission to the registry
March 22, 2024
CompletedFirst Posted
Study publicly available on registry
March 29, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2024
CompletedJuly 3, 2024
July 1, 2024
3 months
March 22, 2024
July 1, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
blood culture contamination rate
false positive peripheral blood culture
three year period
Study Arms (1)
No arm used.
Eligibility Criteria
Children in the 0-18 age group who have been treated for leukaemia as inpatients in the paediatric hermatology oncology clinic and from whom peripheral blood culture was taken for any reason will be included in the study.
You may qualify if:
- within the time interval of the study being a patient between the ages of 0-18,
- not having any other disease other than leukaemia,
- having received inpatient chemotherapy treatment in PHO
- having a peripheral blood culture test taken from the patient,
- the patient's culture results being accessible through the hospital information system.
You may not qualify if:
- the patient was hospitalised in the clinic outside the time frame of the study,
- a diagnosis other than leukaemia
- peripheral blood culture was not taken from the patient or the results could not be accessed through the hospital information system
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ege Universitylead
Study Sites (1)
Ege University
Izmir, 35100, Turkey (Türkiye)
Biospecimen
Peripheral blood culture bottles
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
March 22, 2024
First Posted
March 29, 2024
Study Start
March 15, 2024
Primary Completion
June 1, 2024
Study Completion
June 1, 2024
Last Updated
July 3, 2024
Record last verified: 2024-07